Background This register-based observational study compares dabigatran to warfarin for
secondary stroke prevention in atrial fibrillation patients among both “new starters” on
dabigatran and “switchers” to dabigatran from warfarin. Methods We identified, in nationwide
Danish registries, 2398 patients with atrial fibrillation and a history of stroke/transient
ischemic attack, making a first-time purchase of dabigatran 110 mg twice a day (bid; D110)
and 150 mg bid (D150). Patients were categorized as either vitamin K antagonist (VKA) …